Please assess the completion status of the following clinical trial:

Trial Title: S0802 - Topotecan With or Without Aflibercept in Treating Patients With Extensive-Stage Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically confirmed extensive stage small cell lung cancer~  * Progressive or recurrent disease following one (and only one) standard first-line platinum-containing regimen (cisplatin or carboplatin)~* Measurable or non-measurable disease per RECIST criteria~  * Disease must be outside a previously irradiated field OR a new lesion must be inside the irradiated field~ * Disease must be outside a previously resected area OR a new lesion must be present~* No known brain metastasis unless the metastasis has been treated and is stable for ≥ 3 months prior to study entry~* No leptomeningeal involvement or brain stem metastasis~* Zubrod performance status 0-1~* ANC ≥ 1,500/mm\^3~* Platelet count ≥ 100,000/mm\^3~* Hemoglobin ≥ 10 g/dL~* Serum creatinine ≤ 1.5 times upper limit of normal OR creatinine clearance ≥ 60 mL/min~* Urine protein: creatinine ratio \< 1 OR urine protein \< 500 mg by 24-hour urine collection~* Not pregnant or nursing~* Fertile patients must use effective contraception~* Willing to provide smoking history~* No evidence of active infection~* No active bleeding~* No significant history of bleeding diathesis, including hemoptysis (½ teaspoon of hemoptysis within the past 3 months), or underlying coagulopathy~* No history of recent arterial embolic events, including any of the following:~  * Myocardial infarction~ * Cerebrovascular accident~ * Transient ischemic attack~ * Worsening of pre-existing angina within the past 6 months~* No uncontrolled hypertension (systolic BP \> 150 mm Hg or diastolic BP \> 100 mm Hg)~  * History of hypertension allowed provided it is controlled on anti-hypertensive medications~* No history of congestive heart failure~* No history of encephalitis or encephalopathy of any cause~* No diverticulitis, gastrointestinal bleeding, or peptic ulcer within the past 3 months~* No known AIDS or HIV-1 associated complex~* No known history of immune or immunodeficiency disorders~* No unstable or pre-existing major medical conditions except for cancer-related abnormalities~* No other prior malignancy except for any of the following:~  * Adequately treated basal cell or squamous cell skin cancer~ * In situ cervical cancer~ * Adequately treated stage I or II cancer currently in complete remission~ * Any other cancer from which the patient been disease-free for 5 years~* Concurrent chronic therapeutic doses of low molecular weight heparin allowed~* At least 21 days since prior and no concurrent radiotherapy and recovered~* At least 28 days since prior and no concurrent surgery (e.g., thoracic or other major surgeries) and recovered~* No prior bevacizumab or other anti-angiogenic therapies including, but not limited to, small molecule tyrosine kinase inhibitors~* No concurrent enzyme-inducing anticonvulsant drugs~  * Non-enzyme-inducing anticonvulsant drugs (e.g., Keppra) allowed~* Concurrent chronic oral anticoagulation therapy allowed provided INR is maintained in the therapeutic range (INR 2-3)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm I (ziv-aflibercept, topotecan hydrochloride) (Type: EXPERIMENTAL): Patients receive ziv-aflibercept IV over 1 hour on day 1 and topotecan hydrochloride IV over 30 minutes on days 1, 8, and 15. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity. Patients with responsive or stable disease after 4 courses may then receive ziv-aflibercept IV on day 1 and topotecan hydrochloride IV on days 1 and 8. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
- Arm II (topotecan hydrochloride) (Type: ACTIVE_COMPARATOR): Patients receive topotecan hydrochloride IV over 30 minutes on days 1, 8, and 15. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity. Patients with responsive or stable disease after 4 courses may then receive topotecan hydrochloride IV on days 1 and 8. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.

Based on this trial design, predict the completion outcome and termination type (if applicable).